Assessment of Hematopoietic Recovery Following Chemotherapy for Non-Hodgkin's Lymphoma
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00775957 |
Recruitment Status
:
Terminated
(Terminated by institutional review board)
First Posted
: October 20, 2008
Last Update Posted
: September 28, 2010
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Non-Hodgkin's Lymphoma | Procedure: FLT-PET scan Procedure: FDG-PET scan |
Study Type : | Observational |
Estimated Enrollment : | 35 participants |
Observational Model: | Case Control |
Time Perspective: | Prospective |
Official Title: | Assessment of Hematopoietic Recovery Following Chemotherapy for Non-Hodgknin's Lymphoma |
Study Start Date : | October 2008 |
Group/Cohort | Intervention/treatment |
---|---|
1
FLT-PET Scan
|
Procedure: FLT-PET scan
imaging scan
|
2
FDG-PET Scan
|
Procedure: FDG-PET scan
imaging scan
|
- Staging and ReStaging scans [ Time Frame: after hematopoetic recovery ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- 18 years or older
- Women must not be pregnant or breast feeding
- Histologic diagnosis of non-Hodgkin's lymphoma (any stage)
- Must undergo treatment with chemotherapy and/or radiotherapy
Exclusion Criteria:
- May not have received previous therapy with radiopharmaceuticals
- May not have received prior therapy with cytotoxic chemotherapy and/or monoclonal antibodies

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00775957
United States, Oklahoma | |
University of Oklahoma Health Sciences Center | |
Oklahoma City, Oklahoma, United States, 73104 |
Responsible Party: | Jennifer Holter, MD, University of Oklahoma Health Sciences Center- Dept. of Medicine |
ClinicalTrials.gov Identifier: | NCT00775957 History of Changes |
Other Study ID Numbers: |
FLT-NHL |
First Posted: | October 20, 2008 Key Record Dates |
Last Update Posted: | September 28, 2010 |
Last Verified: | September 2010 |
Additional relevant MeSH terms:
Lymphoma Lymphoma, Non-Hodgkin Neoplasms by Histologic Type Neoplasms |
Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases |